Biochemical measures of ovarian function in female survivors of retinoblastoma treated with intra-arterial melphalan: an initial report. (2nd November 2022)

• Record Type: Journal Article
• Authors: Marathe, Priya H.; Dunkel, Ira J.; Francis, Jasmine H.; Antal, Zoltan; Gobin, Y. Pierre; Abramson, David H.; Friedman, Danielle N.
• Is Part Of: Ophthalmic genetics. Volume 43:Number 6(2022)
• Page Start: 806
• Page End: 808
• Publication Date: 2022-11-02
• Subjects: Retinoblastoma -- survivorship -- ovarian function; Eye -- Diseases -- Genetic aspects -- Periodicals; Eye Diseases -- genetics -- Periodicals; Eye Diseases -- in infancy & childhood -- Periodicals; 617.7
• DOI: 10.1080/13816810.2022.2132516
• Languages: English
• ISSNs: 1381-6810

Abstract

ABSTRACT: Since 2006, ophthalmic artery chemosurgery (OAC) has been used for ocular-sparing treatment of retinoblastoma. Systemic exposure to melphalan is known to cause ovarian dysfunction, but the effect of melphalan-based OAC has not yet been determined. Here, we assess biochemical and symptomatic measures of ovarian function in a cohort of pubertal female survivors of retinoblastoma treated with melphalan-based OAC. These 13 patients all had normal gonadotropins at a median age of 11.1 years, 9.6 years from the completion of therapy. None had symptoms of ovarian dysfunction. This study provides initial evidence that ovarian function remains intact after melphalan-based OAC.